How big is Mersana Therapeutics, Inc.?

As of Jun 18, Mersana Therapeutics, Inc. has a market capitalization of 44.04 million and reported net sales of 34.00 million, with a net profit of -74.01 million. The company has shareholder's funds of -9.51 million and total assets of 144.66 million.

As of Jun 18, Mersana Therapeutics, Inc. has a market capitalization of 44.04 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 34.00 million for the latest four quarters. However, it also recorded a net profit of -74.01 million during the same period.<BR><BR>As of Dec 24, the reporting period shows that Mersana Therapeutics, Inc. has shareholder's funds of -9.51 million and total assets amounting to 144.66 million.

What does Mersana Therapeutics, Inc. do?

Mersana Therapeutics, Inc. is a biotechnology company specializing in the development of antibody drug conjugates (ADCs). As of March 2025, it reported net sales of $3 million and a net loss of $24 million, with a market cap of $44.04 million.

Overview: <BR>Mersana Therapeutics, Inc. is a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -24 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 44.04 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.53 <BR>Return on Equity: 239.76% <BR>Price to Book: -1.43 <BR><BR>Contact Details: <BR>Address: 840 Memorial Dr, CAMBRIDGE MA: 02139-3789 <BR>Tel: 1 617 4980020 <BR>Website: http://www.mersana.com/

Should I buy, sell or hold Mersana Therapeutics, Inc.?

Who are in the management team of Mersana Therapeutics, Inc.?

As of March 2022, Mersana Therapeutics, Inc.'s management team includes Mr. David Mott as Independent Chairman and Ms. Anna Protopapas as President and CEO, along with several Independent Directors on the Board.

As of March 2022, the management team of Mersana Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. David Mott, who serves as the Independent Chairman of the Board.<BR>- Ms. Anna Protopapas, who is the President, Chief Executive Officer, and a Director.<BR><BR>Additionally, the Board of Directors includes several Independent Directors: Mr. Lawrence Alleva, Dr. Willard Dere, Dr. Andrew Hack, Dr. Kristen Hege, and Dr. Martin Huber.

Is Mersana Therapeutics, Inc. overvalued or undervalued?

As of May 9, 2022, Mersana Therapeutics, Inc. is considered risky and overvalued, with key ratios indicating significant concerns, as evidenced by a year-to-date return of -79.44% compared to the S&P 500's positive return of 12.22%.

As of 9 May 2022, Mersana Therapeutics, Inc. has moved from a grade of does not qualify to risky. The company is currently overvalued based on its financial metrics. Key valuation ratios include a Price to Book Value of -1.56, an EV to EBIT of 0.39, and an EV to EBITDA of 0.40, which indicate significant concerns regarding its valuation relative to its peers.<BR><BR>In comparison to its industry peers, Mersana's EV to EBITDA ratio of 0.40 is more favorable than Harpoon Therapeutics, Inc. at -13.4119 and Selecta Biosciences, Inc. at -2.6957, but still reflects a risky valuation environment. The company's stock has underperformed significantly, with a year-to-date return of -79.44% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that Mersana is overvalued in the current market context.

Is Mersana Therapeutics, Inc. technically bullish or bearish?

As of September 8, 2025, Mersana Therapeutics, Inc. shows a mildly bullish technical trend, with mixed indicators across time frames, but has significantly underperformed the S&P 500, raising caution for investors.

As of 8 September 2025, the technical trend for Mersana Therapeutics, Inc. has changed from bullish to mildly bullish. The MACD indicates a mildly bullish stance on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. However, the Bollinger Bands and moving averages present a bearish outlook on the daily, with the daily moving averages specifically indicating bearish momentum. The KST is mildly bullish on the weekly but bearish on the monthly, and the OBV is mildly bullish on the weekly with no trend on the monthly.<BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all time frames, with a year-to-date return of -79.44% versus the S&P 500's 12.22%, and a one-year return of -86.13% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the significant underperformance against the benchmark raises caution.